Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money

This article was originally published in Start Up

Executive Summary

Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.

You may also be interested in...



twoXAR Inc.

TwoXAR Inc. wants to help the biopharma industry make good use of big data. The start-up hopes to change the way drug discovery works, with software that can analyze broad arrays of data – chemical compound libraries, gene expression data, protein interaction networks, protein binding databases, patient records and just about anything else related to drug development – and propose a "short list" of drug candidates with a high probability of making it to the clinic.

Prexton Therapeutics

Prexton Therapeutics aims to advance the standard of care for Parkinson’s disease by developing a therapeutic that strategically targets metabotropic glutamate receptor 4. It plans to use its lead compound as an add-on therapy to facilitate lower therapeutic doses of L-dopa in order to decrease adverse effects, while maintaining the expected therapeutic level of the treatment.

Parkure Ltd.

Parkure Ltd., based in a small lab in Edinburgh, Scotland, will use its fruit fly assay to find new Parkinson’s disease treatments from old drugs, with an aim to slow or even reverse the course of this devastating CNS disorder.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092782

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel